Author

Klaus A. Dugi

Observed names: Dugi, Klaus, Dugi, Klaus A., K A Dugi, K Dugi, K. A. Dugi, K. Dugi, K.A Dugi, K.A. Dugi, KA Dugi, Klaus A Dugi, Klaus Dugi

Observed institutions: Henry M. Jackson Foundation, National Institutes of Health, Boehringer Ingelheim (Germany), Inserm, Institut Pasteur, Philipps University of Marburg, University of Washington, Cornell University, Ferring Pharmaceuticals (Switzerland), Heidelberg University, University Hospital Heidelberg, National Heart, Lung, and Blood Institute, National Institutes of Health Clinical Center, University of Turin

OpenAlex ID: A5111521277

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

2012 · Baptist Gallwitz, Julio Rosenstock, et al. · The Lancet · 341

Effect of linagliptin monotherapy on glycaemic control and markers of β ‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

2010 · S. Del Prato, A. H. Barnett, et al. · Diabetes Obesity and Metabolism · 297

Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study

2010 · M.‐R. Taskinen, J. Rosenstock, et al. · Diabetes Obesity and Metabolism · 293

Die Gutenberg Gesundheitsstudie

2012 · P.S. Wild, T Zeller, et al. · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · 240

Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24‐week randomized study1

2011 · D. R. Owens, R. Swallow, et al. · Diabetic Medicine · 213

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double‐blind, placebo‐controlled study

2011 · R. Gomis, R.‐M. Espadero, et al. · Diabetes Obesity and Metabolism · 177

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase‐4 inhibitor in male type 2 diabetes patients

2009 · T. Heise, E. U. Graefe‐Mody, et al. · Diabetes Obesity and Metabolism · 176

Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease

2007 · M. von Eynatten, P. M. Lepper, et al. · Diabetologia · 172

PDF

Activation of Tubular Epithelial Cells in Diabetic Nephropathy

2002 · Michael Morcos, Ahmed A.R. Sayed, et al. · Diabetes · 157

Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

2021 · Renato D. Lopes, Celestia S. Higano, et al. · Circulation · 156

Decreased Plasma Lipoprotein Lipase in Hypoadiponectinemia

2004 · Maximilian von Eynatten, Jochen G. Schneider, et al. · Diabetes Care · 138

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects

2013 · Leo Seman, Sreeraj Macha, et al. · Clinical Pharmacology in Drug Development · 136

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers

2008 · S. Hüttner, E. U. Graefe‐Mody, et al. · The Journal of Clinical Pharmacology · 134

PDF

Linagliptin (BI 1356), a potent and selective DPP‐4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

2010 · T. Forst, B. Uhlig‐Laske, et al. · Diabetic Medicine · 130

Low Plasma Adiponectin Levels Are Associated With Increased Hepatic Lipase Activity In Vivo

2005 · Jochen G. Schneider, Maximilian von Eynatten, et al. · Diabetes Care · 129

PDF

Human lipoprotein lipase: the loop covering the catalytic site is essential for interaction with lipid substrates.

1992 · K.A. Dugi, H.L. Dichek, et al. · Journal of Biological Chemistry · 128

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus

2013 · Tim Heise, Leo Seman, et al. · Diabetes Therapy · 127

PDF

Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia

1996 · Hartmut H.-J. Schmidt, Suvimol Hill, et al. · The American Journal of Cardiology · 124

Structure, function and role of lipoprotein lipase in lipoprotein metabolism

1994 · Silvia antamarina-Fojo, Klaus A. Dugi · Current Opinion in Lipidology · 124

Human Hepatic and Lipoprotein Lipase: The Loop Covering the Catalytic Site Mediates Lipase Substrate Specificity

1995 · Klaus A. Dugi, Helén L. Dichek, et al. · Journal of Biological Chemistry · 121

Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptor B1

1999 · Gilles Lambert, Michael B. Chase, et al. · Journal of Lipid Research · 113

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator‐controlled, double‐blind study

2011 · R. Kawamori, N. Inagaki, et al. · Diabetes Obesity and Metabolism · 112

Low Hepatic Lipase Activity Is a Novel Risk Factor for Coronary Artery Disease

2001 · Klaus A. Dugi, Karin Brandauer, et al. · Circulation · 99

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects

2012 · Akiko Sarashina, Kazuki Koiwai, et al. · Drug Metabolism and Pharmacokinetics · 86

Therapeutic Response to Medium-Chain Triglycerides and ω-3 Fatty Acids in a Patient With the Familial Chylomicronemia Syndrome

1997 · Mustapha Rouis, Klaus A. Dugi, et al. · Arteriosclerosis Thrombosis and Vascular Biology · 78

Works count: 101

Citation count: 5,599

H-index: 43

I10-index: 68